Table 4.
Five most commonly prescribed first-line treatment regimens, overall and by country.
| Treatment | Overall (N=807) | UK (n=199) | Spain (n=203) | Germany (n=204) | France (n=201) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | |
| Doxorubicin | 330 | 40.9 | 94 | 47.2 | 72 | 35.5 | 107 | 52.5 | 57 | 28.4 |
| Doxorubicin + ifosfamidea | 153 | 19.0 | 31 | 15.6 | 31 | 15.3 | 34 | 16.7 | 57 | 28.4 |
| Docetaxel + gemcitabine | 70 | 8.7 | 16 | 8.0 | 21 | 10.3 | 27 | 13.2 | b | b |
| Paclitaxel | 34 | 4.2 | b | b | 13 | 6.4 | 8 | 3.9 | 10 | 5.0 |
| Ifosfamidea | 33 | 4.1 | 15 | 7.5 | 10 | 4.9 | b | b | b | b |
| Dacarbazine + doxorubicin + ifosfamide | b | b | 11 | 5.5 | b | b | b | b | b | b |
| Dacarbazine + ifosfamidea | b | b | b | b | b | b | 6 | 2.9 | b | b |
| Epirubicin + ifosfamidea | b | b | b | b | b | b | b | b | 17 | 8.5 |
| Trabectedin | b | b | b | b | b | b | b | b | 11 | 5.5 |
NA: not applicable; UK: United Kingdom; amesna was always coadministered with ifosfamide; bmay have been observed in the overall or country-specific sample but was not among the five most commonly prescribed first-line regimens.